Welcome to our dedicated page for Ngm Biopharmaceuticals news (Ticker: NGM), a resource for investors and traders seeking the latest updates and insights on Ngm Biopharmaceuticals stock.
NGM Biopharmaceuticals, Inc. (NGM) has described itself as a biotechnology company focused on discovering and developing novel, life-changing medicines, with all product candidates generated by its in-house discovery engine. The NGM Bio news flow reflects this biology-centric strategy across oncology, liver disease and rare conditions, as well as significant corporate developments affecting the former NGM stock listing.
News coverage for NGM Bio includes updates on its solid tumor oncology programs, such as clinical data from the ongoing Phase 1/2 trial of NGM707, a dual ILT2/ILT4 antagonist antibody product candidate, in combination with KEYTRUDA (pembrolizumab) in advanced or metastatic solid tumors. The company has also reported progress on NGM831 and NGM438, antagonist antibody product candidates targeting ILT3 and LAIR1, respectively, in combination with pembrolizumab.
Investors and observers can also find news items detailing NGM Bio’s work in liver and metabolic diseases, including positive Phase 2b results from the ALPINE 4 trial of aldafermin, an engineered FGF19 analog, in patients with compensated cirrhosis due to NASH, and plans to further develop aldafermin for primary sclerosing cholangitis. Additional updates have covered the potential development of NGM120, a GDF15/GFRAL antagonist antibody product candidate, for hyperemesis gravidarum, a rare and serious pregnancy-related condition.
Another important theme in NGM Bio news is corporate and transaction activity. The company announced an Agreement and Plan of Merger with Atlas Neon Parent, Inc. and Atlas Neon Merger Sub, Inc., affiliates of The Column Group, LP, followed by the closing of a cash tender offer and subsequent merger that resulted in NGM Bio becoming a privately held, wholly-owned subsidiary and its common stock ceasing to trade on Nasdaq.
By reviewing the NGM news feed, readers can track historical announcements on clinical data presentations, conference participation, strategic updates on pipeline prioritization, and the steps that led to the going-private transaction. This provides context on how NGM Bio’s scientific programs and corporate structure have evolved over time.
NGM Biopharmaceuticals (NGM) is making strides in 2021, building on significant progress in 2020 across its therapeutic portfolios—liver and metabolic diseases, retinal diseases, and oncology. The company has initiated pivotal Phase 2b and Phase 3 studies for several product candidates and successfully raised approximately $143.7 million from a public stock offering. Key milestones for 2021 include reporting topline data from its Phase 2b ALPINE 2/3 study and advancing new oncology candidates NGM707 and NGM438. Currently, NGM holds around $425 million in cash, bolstering its clinical pipeline.
NGM Biopharmaceuticals, Inc. (NGM) has priced an underwritten public offering of 4,629,630 shares of its common stock at $27.00 per share, aiming for approximately $125 million in gross proceeds. The offering is set to close on or about January 8, 2021, pending customary conditions. There is a 30-day option for underwriters to purchase an additional 694,444 shares. Goldman Sachs, Citigroup, and Cowen are joint book-running managers, with Raymond James and B. Riley Securities as lead managers. The offering is registered under an effective shelf registration statement with the SEC.
NGM Biopharmaceuticals, Inc. (NGM) has announced a public offering of $100 million in common stock, with an additional $15 million option for underwriters. All shares will be sold by NGM, which is subject to market conditions. Goldman Sachs, Citigroup, and Cowen are managing the offering. The shares will be offered under a previously filed shelf registration statement with the SEC. NGM focuses on developing therapeutics for liver diseases, metabolic disorders, retinal diseases, and cancer.
NGM Biopharmaceuticals has introduced NGM438, a new antibody candidate targeting LAIR1, during its inaugural R&D Day. LAIR1 is implicated in tumor-associated immune suppression. The company aims to initiate first-in-human trials for NGM438 in Q4 2021. NGM438 is designed to enhance anti-tumor immunity by disrupting LAIR1-collagen interactions, which may improve responses to current immunotherapies. Alongside NGM438, NGM707 and NGM120 are part of its oncology pipeline, focusing on reversing immune suppression.
NGM Biopharmaceuticals will host a virtual R&D Day on December 9, 2020 at 12:00 pm ET, showcasing its multi-therapeutic pipeline. The event will highlight key drug candidates addressing unmet patient needs in liver and metabolic diseases, retinal diseases, and cancer, including aldafermin and MK-3655, NGM621, NGM120, and NGM707. Notable speakers include distinguished industry physicians and executives from Merck. The event will be streamed live, with a replay available on the NGM website for one year.
NGM Biopharmaceuticals reported positive results from its Phase 1 study of NGM621, an anti-complement C3 antibody for geographic atrophy. The treatment showed a favorable safety profile, with no serious adverse events or intraocular inflammation. The serum pharmacokinetics were linear and dose-proportional, supporting a potential dosing regimen of every eight weeks. The ongoing Phase 2 CATALINA study has begun enrollment, with the first patient dosed in July 2020. NGM621 may offer significant advantages in treating this progressive retinal disease.
NGM Biopharmaceuticals (NGM) reported significant advances in its therapeutic pipeline as of September 30, 2020. The company initiated a Phase 2 clinical trial for NGM621 targeting geographic atrophy and expanded its oncology portfolio with NGM707, an immuno-oncology candidate. Financially, NGM reported a net loss of $29.8 million, up from $10.9 million in 2019, while research and development expenses surged to $47 million. NGM's cash reserves stood at $287.9 million, down from $344.5 million at year-end 2019, emphasizing ongoing investments in its expanding pipeline.
NGM Biopharmaceuticals (NGM) announced that CEO David J. Woodhouse, Ph.D., will present at three investor conferences. The presentations are scheduled for:
- November 18, 2020: Jefferies Virtual London Healthcare Conference at 12:00 PM ET
- November 18, 2020: Stifel Virtual Healthcare Conference at 2:40 PM ET
- November 23, 2020: 32nd Annual Piper Sandler Virtual Healthcare Conference at 12:00 PM ET
A live webcast will be available on the NGM website, and a replay of the presentation will be archived for 90 days.
NGM Biopharmaceuticals announced the upcoming poster presentation of its Phase 1 study on NGM621, a monoclonal antibody targeting complement C3, at the American Academy of Ophthalmology (AAO) 2020 Virtual event. The study focuses on its safety, tolerability, and pharmacokinetics in patients with geographic atrophy (GA). The presentation is scheduled for Nov. 13, 2020. NGM621 is engineered for potential extended dosing and aims to address issues arising from complement system dysregulation. The company is committed to advancing innovative therapeutics in retinal diseases and other conditions.
NGM Biopharmaceuticals, Inc. (Nasdaq: NGM) announced multiple presentations of aldafermin at AASLD’s The Liver Meeting, scheduled for Nov. 13-16, 2020. A late-breaking oral presentation will showcase results from the 24-week Phase 2 study on aldafermin in patients with non-alcoholic steatohepatitis (NASH). The study's findings indicate significant anti-fibrotic responses in patients with advanced fibrosis. Additional presentations will cover lipid management and improvements in non-invasive measures related to NASH. Aldafermin aims to address liver disease by targeting multiple pathways, demonstrating promising clinical efficacy.
